Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL29414090 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL29358024 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL30554804 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL29599870 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL8541 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL5605456 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL1923763 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL8524 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL5904190 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL19469972 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4009973-B1 | PHARMACEUTICAL COMPOSITIONS OF (6AS)-6-METHYL-5,6,6A,7-TETRAHYDRO-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL | ACLIPSE ONE INC (US) | 2025-01-29 | — | — | EP | claimed |
| US-20230141988-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | ACLIPSE ONE INC. | 2023-05-11 | — | — | US | claimed |
| US-20220313682-A1 | Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol | ACLIPSE ONE INC. | 2022-10-06 | — | — | US | claimed |
| US-11459301-B2 | Crystalline form of s-apomorphine | ACLIPSE ONE, INC. (US) | 2022-10-04 | — | — | US | claimed |
| CN-114980896-A | Pharmaceutical composition of (6AS) -6-methyl-5, 6,6A, 7-tetrahydro-4H-dibenzo [ de, g ] quinoline-10, 11-diol | 阿克里普斯一有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220265635-A1 | TREATMENT OF NEUROLOGICAL DISEASE | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-08-25 | — | — | US | claimed |
| EP-4009973-A1 | PHARMACEUTICAL COMPOSITIONS OF (6AS)-6-METHYL-5,6,6A,7-TETRAHYDRO-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL | Aclipse One, Inc. (US) | 2022-06-15 | — | — | EP | claimed |
| US-20210353613-A1 | TREATMENT OF NEUROLOGICAL DISEASE | THE UNIVERSITY OF SHEFFIELD (GB) | 2021-11-18 | — | — | US | claimed |
| WO-2021026421-A1 | PHARMACEUTICAL COMPOSITIONS OF (6AS)-6-METHYL-5,6,6A,7-TETRAHYDRO-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL | ACLIPSE ONE INC. (US) | 2021-02-11 | — | — | WO | claimed |
| WO-2021026413-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | ACLIPSE ONE INC. (US) | 2021-02-11 | — | — | WO | claimed |
| WO-2020081975-A1 | TREATMENT OF NEUROLOGICAL DISEASES | ACLIPSE ONE INC. (US) | 2020-04-23 | — | — | WO | claimed |
| WO-2025024816-A1 | TREATMENT OF NEUROLOGICAL DISEASES | ACLIPSE ONE INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025024816-A1 | TREATMENT OF NEUROLOGICAL DISEASES | ACLIPSE ONE INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-4009973-B1 | PHARMACEUTICAL COMPOSITIONS OF (6AS)-6-METHYL-5,6,6A,7-TETRAHYDRO-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL | ACLIPSE ONE INC (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-4009973-B1 | PHARMACEUTICAL COMPOSITIONS OF (6AS)-6-METHYL-5,6,6A,7-TETRAHYDRO-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL | ACLIPSE ONE INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20150272939-A1 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase | YALE UNIVERSITY (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150272939-A1 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase | YALE UNIVERSITY (US) | 2015-10-01 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011084846-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459301-B2 | Crystalline form of s-apomorphine | SRI, IAPP, SORT1 | DRD2 377/4885DRD4 423/4885DRD3 436/4885 |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | DRD2 756/4885DRD4 639/4885DRD3 714/4885 |
| US-20220265635-A1 | TREATMENT OF NEUROLOGICAL DISEASE | HSF1, HSPD1, HSPH1 | DRD2 2697/4885DRD4 3164/4885DRD3 3411/4885 |
| US-20210353613-A1 | TREATMENT OF NEUROLOGICAL DISEASE | SOD1, SMN1; SMN2, SOD3 | DRD2 1267/4885DRD4 1266/4885DRD3 1554/4885 |
| US-20230141988-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PARK7, SNCA, ATXN10 | DRD2 206/4885DRD4 452/4885DRD3 520/4885 |
| US-20220313682-A1 | Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol | CYP2D6, UGT1A7, UGT2B7 | DRD2 10/4885DRD4 20/4885DRD3 26/4885 |
| US-20150272939-A1 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase | KDM1B, KDM1A, JMJD1C | DRD2 2832/4885DRD4 3283/4885DRD3 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.